Stock CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Creative Medical Technology Holdings, Inc.

Equities

CELZ

US22529Y4089

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
3.59 USD +4.06% Intraday chart for Creative Medical Technology Holdings, Inc. -5.76% -22.12%
Jun. 24 Creative Medical Successfully Generated Human Ipsc-Derived Islet Cells That Produce Human Insulin RE
Jun. 24 Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Creative Medical Technology Holdings Provides Corporate Update
AQ
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
AQ
Creative Medical Technology Holdings Provides Corporate Update
BU
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
BU
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
BU
Creative Medical Technology Holdings Provides Corporate Update
PR
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine using AlloStem Novel Cell Therapy to Treat Chronic Lower Back Pain
AQ
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain
PR
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine using AlloStem for the Treatment of Chronic Lower Back Pain
AQ
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain
PR
Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements
PR
Creative Medical Technology Announces $2 Million Share Repurchase Program
PR
Creative Medical Technology Holdings Provides Corporate Update
PR
Creative Medical Technology Holdings Announces Reverse Stock Split
PR
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform
PR
Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz Platform Development
AQ
Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development
PR
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine Procedure Using AlloStem Allogenic Cell Line
AQ
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line
PR
Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CELZ Stock
  4. News Creative Medical Technology Holdings, Inc.
  5. Press Releases